期刊文献+

新型蛋白酪氨酸激酶抑制剂类抗肿瘤药物的研究进展 被引量:14

Progress of research on the new protein tyrosine kinase inhibitor antitumor drugs
下载PDF
导出
摘要 目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。方法综述了最新发现的小分子酪氨酸激酶抑制剂的化学结构、抗肿瘤作用及其作用机制及其发展方向等内容。结果结论蛋白酪氨酸激酶与细胞的增殖、分化、迁移和凋亡有着密切的关系,在细胞生命活动的信号转导途径中扮演着十分关键的角色,筛选酪氨酸激酶抑制剂已经成为开发抗肿瘤药物的新途径。 Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK). Methods This article reviewed some new tyrosine kinase inhibitors (TKI) about their chemical structures, anticancer-effect; mechanism of action and development. Results and Conclusions Protein tyrosine kinase (PTK) plays very important role in cellular multiplication, differentiation, immigration and apoptosis closely, which acts as an important role in the cellular significance signal transduction pathway. So screening of tyrosine kinase inhibitor (TKI) has become a new channel to exploit new anti-cancer drugs.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2007年第7期451-456,共6页 Journal of Shenyang Pharmaceutical University
基金 沈阳市科学技术计划项目(1053125-1-42)
关键词 蛋白酪氨酸激酶 酪氨酸激酶抑制剂 信号转导 抗肿瘤药物 protein tyrosine kinase tyrosine kinase inhibitor (TKI) signal transduction anticancer drug
  • 相关文献

参考文献36

二级参考文献221

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量:9
  • 2彭珧,张怡轩,郑更新.新型蛋白酪氨酸激酶抑制剂类抗肿瘤药物的研究进展[J].沈阳药科大学学报,2007,24(7):451-456. 被引量:14
  • 3[1]Grandis JR,Melham MF,Gooding WE,et al.Levels of TGF-αand EGFR protein in head and neck squamous cell carcinoma and patient survival.J Natl Cancer Inst (Bethesda),1998,90(11)∶824-832.
  • 4[2]Ryan PD,Chabner BA.On receptor inhibitors and chemotherapy.Clin Cancer Res,2000,6(12)∶4607-4609.
  • 5[3]Mendelsohn J.Blockade of receptors for growth factors:An anticancer therapy-The fourth annual Joseph H.Burchenal American Association for Cancer Research Clinical Research Award Lecture.Clin Cancer Res,2000,6(3)∶747-53.
  • 6[4]Inoue K,Slaton JW,Perrotte P,et al.Paclitaxel enhance the effect of the anti-epidermal growth factor receptor monoclonal antibody Imclonec225 in mice with metastatic human bladder transitional cell carcinoma.Clin Cancer Res,2000,6(12)∶4874-4884.
  • 7[5]Baselga J,Norton L,Masui H,et al.Antitumor effects of doxorubicin in combination with anti-epidernal growth factor receptor monoclonal antibodies.J Natl Cancer Inst,1993,85(16)∶1327-1333.
  • 8[6]Fan Z,Baselga J,Masui H,et al.Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.Cancer Res,1993,53(19)∶4637-4642.
  • 9[7]Bruns C,Harbison M,Davis D,et al.Epidermal growth factor receptor blockede with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing othotopically in nude mice by antiangiogenic mechanisms.Clin Cancer Res,2000,6(5)∶1936-1948.
  • 10[8]Baselga J,Pfister D,Cooper M,et al.Phase Ⅰ studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and combination with cisplatin.J Clin Oncol,2000,18(4)∶904-914.

共引文献113

同被引文献238

引证文献14

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部